3D-PharmXchange is a consultancy firm that enables life science companies to bring new medicines to market. They have years of expertise and specialist knowledge to draw on. Helping clients to secure a successful strategic launch in the pharmaceutical industry, negotiating the various hurdles and challenges on the way.
Our motivation is to bring medicines to the market and the patient faster by close collaboration with all stakeholders
The company offers the flexible deployment of specialised consultants in core disciplines within drug development including Non-Clinical (Toxicology, ADME), CMC (Chemistry, Manufacturing and Controls), RA (Regulatory Affairs) and Clinical Development.
François van Och, one of the three managing partners, explains: “By offering independent strategic project management, you are a credible advocate for clients and their projects. This creates synergy between the disciplines and intensive collaboration with the parties we work for. And that’s important for an effective time and cost-efficient process.”
The Move to Pivot Park
Founders Inez de Greef and Ronald van der Geest spent many years in the pharmaceutical and biotech industry before they decided to set up 3D-PharmXchange in 2010. At the time, they saw more and more pharmaceutical companies abandoning their Research & Development. Novel and innovative drug candidates were mostly generated by agile, small start-ups and bio-techs.
Seeing the opportunities, De Greef and Van der Geest quickly realised that their broad knowledge of drug development and their familiarity with getting the medicines to market could be used to advise and guide a broad range of clients. In 2011, expert toxicologist van Och joined the company and became part of the management team in 2016. Originally based in Tilburg, 3D-PharmXchange opened a second office at Pivot Park the moment an office was available on the specialised life science hub.
“The moment R&D MSD/Organon left Oss and a Life Sciences Park was born, we felt a responsibility to open an office there. Because of our connections with MSD/Organon, we knew a lot of people who had worked for MSD/Organon and we wanted to support the initiatives of our former colleagues. A logical step as we already had considerable experience in specific disease areas.”
An ever expanding client portfolio
In the past twelve years, 3D-PharmXchange has developed a varied client portfolio, including a variety of companies based at Pivot Park. Clients range from one-man biotech start-ups to top-10 international pharma companies. With this growth of clients, the number of employees has also increased, “We now have about 23 employees. To guarantee continuity, you must have a minimum critical mass within the services you offer.”
Van Och thinks growth will continue for a while, although he notes that finding qualified employees could become a problem. “When we want to grow organically, it would be ideal if we can continue our current work taking on innovative and challenging projects together with interesting partners and clients.” And he concludes: “Within our company, it’s not just about the assignment. All our activities are designed around people, the employee, the client and the patient. The employee as our biggest asset, working in close collaboration with the client and together try to achieve our core ambition, the development of innovative and effective medicines brought to patients with efficiency and timeliness.”
3D-PharmXchange is a Dutch drug development company that partners with bio-techs, start-ups and bigger pharmaceutical firms. They provide independent development expertise and specialisms ranging from small molecules and biotechnology products to ATMPs and oligonucleotides. 3D-PharmXchange helps asking the right questions once a lead candidate is identified and will guide development programs toward approval. Furthermore, the company provides its clients with management support to ensure commercial success.